Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade

Takigawa, Hiroshi; Kitayama, Michio; Wada‐Isoe, Kenji; Kowa, Hisanori; Nakashima, Kenichiro

doi:10.1002/brb3.557

Cited by 46 publications

(63 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a study in Japan that included other PSP phenotypes in addition to PSP-RS found a total prevalence of 18 per 100,000 across all ages. 5 This higher prevalence number is consistent with estimates from autopsy series, 6 and suggests that the prevalence of the full spectrum of PSP syndromes is substantially higher than estimates based on PSP-RS alone. A cluster of PSP cases in an industrial city in France and a multicenter case-control study suggest that environmental risk factors influence PSP incidence.…”

Section: Introductionsupporting

confidence: 73%

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Boxer

Golbe

et al. 2017

The Lancet Neurology

362

359

View full text Add to dashboard Cite

Progressive supranuclear palsy (PSP), once simply considered a common cause of atypical parkinsonism is now recognized as a spectrum of motor and behavioral syndromes associated with a specific four repeat (4R) tau neuropathology at autopsy. There are currently no effective treatments for PSP, but because PSP is strongly linked biochemically and genetically to tau protein abnormalities, there is a growing interest in pursuing clinical trials of new tau-directed therapies for this disorder. Such new tau therapies are envisioned to have disease-modifying effects by reducing brain levels of toxic forms of tau or compensating for loss of tau function. To be most effective, these treatments will need to be initiated at early stages of disease. New research criteria that recognize early forms of PSP and operationalize diagnosis of the full spectrum of clinical phenotypes have recently been published. These criteria and new clinical trial designs have benefited from rapid advances in MRI, physiological and fluid biomarker development for PSP. As tau pathology is also central to Alzheimer’s disease and chronic traumatic encephalopathy, it is believed that a successful tau therapeutic for PSP would inform the treatment of other neurodegenerative diseases.

show abstract

Section: Introductionsupporting

confidence: 73%

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Boxer

Golbe

et al. 2017

The Lancet Neurology

362

359

View full text Add to dashboard Cite

show abstract

“…The analysis of gender distribution resulted in a greater proportion of the PSP diagnosis for male patients over the entire observation period with a maximum peak in 2012 with 60.6% male patients. In the analysis of Takigawa et al, comparable rates for gender distribution with more male patients affected were observed [ 16 ]. In other studies, these data were not sufficiently documented [ 16 , 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

“…In the analysis of Takigawa et al, comparable rates for gender distribution with more male patients affected were observed [ 16 ]. In other studies, these data were not sufficiently documented [ 16 , 20 , 21 ]. The mean age of hospitalized PSP patients only varied between 72.3 and 73.4 years over the entire period of analysis.…”

Section: Discussionmentioning

confidence: 99%

“…The study of Golbe et al in two New Jersey counties in the US yielded a prevalence of 1.39 [ 14 ]. Two Japanese studies collected epidemiological PSP data of all phenotypes in Yonago City where the prevalence of 5.8/100,000 in 1999 [ 15 ] rose to 17.9/100,000 in 2010 [ 16 ]. In London, UK, 6.4 PSP cases per 100,000 were detected based on records of general practices [ 17 ] and in a more recent analysis in two UK counties for frontotemporal lobar degeneration syndromes, PSP was found to have a prevalence of up to 18 per 100,000 people in the age group between 70 and 74 [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017

Zella

Bartig²,

Herrmann

et al. 2020

JCM

View full text Add to dashboard Cite

Progressive supranuclear palsy (PSP) belongs to the disease spectrum of Parkinsonian syndromes. Due to the chronic and progressive neurodegenerative course of the disease, PSP patients often have to be hospitalized to undergo diagnostic and therapeutic measures. The dynamics and characteristics of PSP inpatient treatment in Germany have not been investigated thus far. The current study analyzed trends of inpatient treatment in Germany for the years 2010–2017 based on the German DRG statistics (“diagnostic-related groups”) in the category G23.- (other degenerative diseases of the basal ganglia) and with special focus on PSP (G23.1). Inpatient case numbers of the G23.- category comprised a total of 21,196 patients from 2010–2017, whereas the PSP subcategory (G23.1) amounted to 10,663 cases. In the analyzed time period, PSP patient numbers constantly increased from 963 in 2010 to 1780 in 2017 with yearly growth rates of up to 20%. Similar trends were observed for other Parkinsonian syndromes such as multiple system atrophy (MSA). Differentiating PSP inpatients by gender demonstrated a higher proportion of males (55–60%) in comparison to female patients for the entire observation period. The average age of hospitalized PSP patients over these years was between 72.3 and 73.4 years without relevant differences for gender. The most common comorbidities consisted of cardiovascular, neurological, muscular and urological disorders. In summary, the analysis demonstrates that PSP patients are increasingly hospitalized in Germany and the current concepts of stationary care have to differentiate standard practices for Parkinson’s disease (PD) to also address the needs of patients with PSP and other Parkinsonian syndromes.

show abstract

“…These values reflect however only Richardson's syndrome (RS). In a recent study in Japan that also assessed cases with PSP and progressive gait freezing (PSP‐PGF), the prevalence of PSP was estimated at 17.9 per 100,000 . Recent estimations of incidence, ranging from 0.14 to 1.2 per 100,000 person‐years, do exist, but they also reflect the incidence of RS rather than PSP .…”

Section: Psp: Milestones Of the Recent 10 Yearsmentioning

confidence: 99%

One decade ago, one decade ahead in progressive supranuclear palsy

2019

View full text Add to dashboard Cite

Fifty‐five years have passed from the first description of PSP, but it is in the last decade that there has been a revolutionary change in understanding both clinical and pathophysiological aspects of this disease. Ten years ago, our knowledge about the clinical spectrum and pathophysiology of the disease was quite limited, and there was no credible clinical study on any drug treatment for this devastating disease. Today, we have discovered the wide clinical spectrum of PSP, and this led to the development of new diagnostic criteria in 2017, aiming to diagnose the disease earlier and include more phenotypes into clinical studies. Moreover, just over the past 10 years, numerous large, double‐blind, clinical trials with disease‐modifying agents have been conducted that provided important novel insights into disease biomarkers and progression. These studies were possible because of gained novel insights into pathophysiological processes of the disease and pave the way for the near future. In the next decade, we dare to predict the discovery of biomarkers for PSP, improvements in diagnosis using the new criteria in combination with these biomarkers, and ultimately the development of a neuroprotective therapy that could be applied to patients in a prodromal stage and spare them from this devastating disorder. © 2019 International Parkinson and Movement Disorder Society

show abstract

Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade

Cited by 46 publications

References 21 publications

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017

One decade ago, one decade ahead in progressive supranuclear palsy

Contact Info

Product

Resources

About